Summary
The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate.
At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation.
It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brodie RR, Chasseaud LF, Elsom FF, Franklin ER, Taylor T (1976) Antilipidemic drugs. Arzneimittelforsch (Drug Res) 26: 896–901
Brown MS, Golstein JL (1987) The Hyperlipoproteinemias and other disorders of the lipid metabolism. In: Harrison's principles of internal medicine, 11th edn. Mc Graw Hill
Consensus Conference on: Lowering Blood Cholesterol to Prevent Heart Disease (1985) J Am Med Assoc 253: 2080–2086
Cotta Ramusino AM, Carozzi A (1986) A simple and rapid method for determining procetofenic acid, an active metabolite of procetofen in biological fluids by solid phase extraction and HPLC. J Chromatogr 383: 419–424
Desager JP, Harvengt C (1978) Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 16: 570–574
Drouin P, Mejean L, Lambert D, Sauvanet JP, Debry G, Tourne C, Wulfert E (1979) Drug plasma levels and hypocholesterolemic effect of fenofibrate in patients with type IIA hyperlipoproteinemia. Curr Thera Res 26: 357–362
Gidez LI, Miller G, Burstein M, Slagle S, Eder HA (1982) Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23: 1206–1223
Grundy SM (1986) Cholesterol and coronary heart disease. J Am Med Assoc 256: 2849–2858
Harvengt C, Heller F, Desager JP (1980) Hypolipemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemia. Artery 7: 73–82
Heller F, Harvengt C (1983) Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lypolitic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 25: 57–63
Kritchewsky D (1980) Pharmacologie du fenofibrate. Nouv Press Med 9: 3769–3773
Malmendier CL, Delcroix C (1985) Effects of fenofibrate on high and low density lipoprotein metabolism in heterozigous familial hypercholesterolemia. Atherosclerosis 55: 161–169
Micheli H, Pometta D, Gustafson A (1980) Activite du fenofibrate dans quatre types d'hyperlipoproteinemie et sur les apoproteines A et B dans le type IIA. Nouv Press Med 9: 3759–3762
Paoletti R, Franceschini G, Sirtori C (1983) Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high density lipoproteins levels. Am J Cardiol 52: 21B-27B
Rifkind BM, Lenfant C (1986) Cholesterol lowering and the reduction of coronary heart disease risk. J Am Med Assoc 256: 2872–2873
Rossner S, Oro L (1981) Fenofibrate therapy of Hyperlipoproteinaemia. A dose — response study and a comparison with clofibrate. Atherosclerosis 38: 273–282
Rubba P, Falanga A, Postiglione A, Patti L, Mancini M (1982) Increase of lipoproteinlipase activity after procetophen (Fenofibrate) treatment in primary hyperlipoproteinemia. Clin Ther Cardiovasc 2: 177–179
Schneider A, Stange EF, Ditschuneit HH, Ditschuneit H (1985) Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 56: 257–262
Sheperd J, Caslake MJ, Ross Lorimer A, Wallance BD, Packard CJ (1985) Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Atherosclerosis 5: 162–168
Sommariva D, Bonfiglioli D, Pogliaghi I, Ottomano C, Fasoli A (1984) Fenofibrate therapy of hypertriglyceridaemias. Differential effects on LDL cholesterol level in Type IV and Type IIb primary hyperlipoproteinaemia. Eur J Clin Pharmacol 26: 741–744
Wilson PWF, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr. (1985) Estimation of VLDL cholesterol in hyperlipidemia. Clin Chim Acta 151: 285–291
Wulfert E, Boissard G, Legendre C, Baron C (1981) Inhibition of membrane — bound hepatic 3 hydroxy 3-methyl glutaryl CoA reductase as the consequence of altered membrane fluidity. Artery 9: 120–131
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bertolini, S., Elicio, N., Daga, A. et al. Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb. Eur J Clin Pharmacol 34, 25–28 (1988). https://doi.org/10.1007/BF01061412
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01061412